Media
Aducanumab and the Business of Alzheimer Disease; Implicit Light Sensitivity in Migraine
"Why does it take an expensive drug of uncertain benefit... to finally put some cash into what we should have been (Memory Centers) the past 20, 30 years?" said Dr. Jason Karlawish on the Neurology Podcast.
Jason Karlawish’s new book examines “The Problem of Alzheimer’s: How Science, Culture, and Politics Turned a Rare Disease Into a Crisis and What We Can Do About It”
Dr. Karlawish answers questions about his book and the impact of US policy on dementia care.
A Conversation with Dr. Jason Karlawish
In this episode of the Nocturnists, Dr. Karlawish discusses the mounting practical, moral, and ethical quandaries of caring for patients with Alzheimer’s and other dementia-causing diseases.
The emotional and financial cost of dementia demands our community’s attention
Geriatrician Dr. Kara Kuntz connects the topics Dr. Karlawish’s book to her community.
The Problem of Alzheimer's Follow-up Q & A
Dr. Karlawish answers questions from members of the Maris Grove community about caregiving, the theory of extended mind, and healthy brain aging.
The Problem of Alzheimer’s
Dr. Karlawish discussed Alzheimer's disease as a disease of autonomy on Afternoon Tea with Docs. He said, "the disease chips away at a person's ability to self-determine her life."
How a Rare Disease Became a Crisis
"I don't think we're going to drug our way out of this complicated disease, but there are things we can do right now to live with dementia," said Dr. Jason Karlawish on the Hey, Boomer! podcast.
America’s Healthcare Crisis
Dr. Jason Karlawish was a guest on the Patti Brennan Show. Dr. Karlawish discussed the need for long-term care social insurance, the stigma of Alzheimer's disease, and more.
Seeking Early Signals of Dementia in Driving and Credit Scores
Dr. Jason Karlawish offers his opinion on driving performance as a predictor of Alzheimer’s disease.
Aducanumab (Aduhelm) for the Treatment of Alzheimers: A Podcast with Aaron Kesselheim and Jason Karlawish
On the GeriPal Podcast, Dr. Jason Karlawish dissects Aduhelm's approval, which he refers to as a "bridge to far too soon," and Aduhelm's pricing.
At Home, On Air featuring anne basting and jason karlawish
Dr. Jason Karlawish and his colleague Dr. Anne Basting were featured guests on the inaugural episode of At Home, On Air.
Risks and benefits of aducanumab for alzheimer’s disease
Dr. Jason Karlawish explains why he is a “reluctant prescriber” of Aduhelm and talks listeners through the controversies surrounding Aduhelm’s approval.
Cleveland Clinic, Mount Sinai and Providence Won’t Give Biogen’s New Alzheimer’s Drug
"It’s very disturbing that we’re starting to hear health systems that rely on the FDA sending signals that they don’t trust the FDA,” Dr. Jason Karlawish told The Wall Street Journal.
Recently Approved Alzheimer Drug Raises Questions That Might Never Be Answered
In JAMA Network Medical News, Dr. Jason Karlawish expresses his concern over Aduhelm’s potential effect on enrollment of future clinical trials.
Lockdown dementia with Jason Karlawish and Jennifer Watt
On the Deep Breath Podcast, Dr. Jason Karlawish discusses the negative impact of social isolation brought on by the pandemic for older adults and explains the importance of visitors for those living in a facility.
Aduhelm, Biogen’s new Alzheimer’s drug, won FDA approval. Now doctors, patients, and insurers face tough decisions about care and cost
“I remain an unenthusiastic prescriber (of Aduhelm),” Dr. Jason Kalrawish told The Philadelphia Inquirer. But, he added, “I have to respect that one of my chief goals is to help people maintain their autonomy.”
Alzheimer's Doctors On Biogen's New Drug; Tax Inequality
There's excitement — and controversy — surrounding Biogen's new Alzheimer's drug. What are doctors saying? Dr. Jason Karlawish talks about the drug's promise and peril.
Should the FDA Have Approved the New Alzheimer’s Drug?
In an event hosted by The Hastings Center, Dr. Jason Karlawish discusses the impact of Aduhelm’s approval on clinical practice and the field of Alzheimer’s disease research.
A NEW ALZHEIMER’S DRUG OFFERS MORE QUESTIONS THAN ANSWERS
Dr. Jason Karlawish describes the ethical dilemmas in prescribing Aduhelm to patients and the controversy surrounding the drug.
"לבנות על תרופה לאלצהיימר זה כמו לתכנן את העתיד על סמך זכייה בלוטו"
Dr. Jason Karlawish discussed the FDA’s approval of Aduhelm with Haaretz. This article is in Hebrew and has a paywall.
Aduhelm, Biogen’s new Alzheimer’s drug, won FDA approval. Now doctors, patients, and insurers face tough decisions about care and cost
It’s unclear when the drug will be available or whether insurance will pay for it, yet it is eagerly awaited by many seeking options to treat an unrelenting disease.
"A disease does not fully exist in America until it has a business model"
In Episode XX of the podcast Whiskey & Cream the host, Ari Shapiro, dives into the topic of Biogen's Aduhelm. Aduhelm arrived like a bolt out of the blue and changed the way the world is looking at Alzheimer's disease.
What’s on the Horizon for Dementia Care? with Dr. Jason Karlawish
In today’s episode, Dr. Karlawish discusses potential breakthroughs in the years ahead that can help us weather this storm. We also review the FDA’s controversial approval last week of aducanumab, the first new drug for Alzheimer’s in nearly two decades.
Alzheimer's disease drug approved in the US despite concerns of clinicians
The US Food and Drug Administration has approved the first drug for Alzheimer's disease in nearly two decades. But not everyone is welcoming the decision including one of our guests Dr. Jason Karlawish.
The FDA Just Approved A Major Alzheimer's Drug. Now What?
On Monday, the FDA approved aducanumab, a new medication for Alzheimer's. But the FDA's approval comes despite an intense debate. Dr. Jason Karlawish discusses what we know about the drug and how it will shape the future of Alzheimer's research and treatment.
Listen: Two Alzheimer’s experts with opposing viewpoints on Aduhelm
This week’s “First Opinion Podcast” is a special two-part episode focusing on the controversial — some say inflammatory — FDA decision to approve aducanumab. In this episode, two episodes, Patrick Skerrett talks with Dr. Jason Karlawish, who does not believe the drug is ready to be approved.
5 Things to Know About the New Alzheimer's Drug, Aducanumab
Doctors weigh in on Biogen's newly approved dementia treatment, brand name Aduhelm. "So if you take this drug, you're taking a risk that's unusual when you take a drug, and that risk is the drug may have no benefit,” says Jason Karlawish in this AARP article.
Why The FDA’s Approval Of A New Alzheimer’s Drug Should Worry You
Aduhelm may be a case study in everything that’s wrong with how America manages prescription drugs. “The results of studies of aducanumab don’t allow reasonable conclusions about the count of days of active life a person living with Alzheimer’s disease will receive from taking the drug,” said Dr. Jason Karlawish.
WHAT’s NEXT FOR ALZHEIMER’S DISEASE? A conversation with PETER BOWES
There has been “spectacular” progress in the understanding and treatment of Alzheimer’s. In this LLAMA podcast hosted by Peter Bowes, Dr. Jason Karlawish says therapeutic treatments have had significant gains, but hurdles remain.
Alzheimer's Disease: care, treatment and prevention
The FDA approved use of the controversial Alzheimer's drug Aduhelm. We'll speak with Dr. Jason Karlawish about the decision and why it generated much debate. We'll also discuss the state of Alzheimer's research and treatment, particular the ethical issues that arise with the disease, and the toll Alzheimer's takes on caregivers. Karlawish's new book is “The Problem of Alzheimer's.”
The F.D.A.’s Extraordinary Approval of a Questionable Treatment for Alzheimer’s
It is very rare for the agency to ignore an overwhelmingly negative advisory recommendation. Dr. Jason Karlawish, a co-director of the University of Pennsylvania’s Penn Memory Center, in Philadelphia, who ran one of the trial sites, was quoted for his opinion.
Dementia, Alzheimer’s have reached crisis point, Penn researcher says. Here’s what we can do about it. | 5 Questions
Sandy Bauers, For The Inquirer, asked Dr. Jason Karlawish 5 questions about how mild cognitive impairment, dementia, and Alzheimer’s now affect so many people — those with symptoms, plus their caretakers — and why he terms it a crisis.
FDA Approves First New Alzheimer’s Drug in Nearly Two Decades
Biogen drug approved after facing doubts over whether it slows the progression of the memory-robbing disease. Dr. Jason Karlawish and other experts talk to WSJ about Aducanumab.
What You Need to Know About the New Alzheimer's Disease Drug
A new drug to treat Alzheimer’s Disease received FDA approval. NBC10’s Jim Rosenfield spoke with Jason Karlawish of the Penn Memory Center who discussed concerns about raising false hopes for patients and families.
The FDA Has Approved A New Alzheimer's Drug — Here's Why That's Controversial
The Food and Drug Administration approved the drug aducanumab to treat patients with Alzheimer's disease on Monday. Dr. Jason Karlawish speaks to NPR about the drug, his opinions, and what the future may look like now that it is approved.
The First Treatment for Alzheimer’s Disease Is Here
Alzheimer’s disease was first described by Alois Alzheimer in 1906, and now, more than 100 years later, doctors have an effective drug to treat the cognitive disorder. Find out the experts opinions and the possible future of Alzheimer’s with TIME.